Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Research Protocols

Date Submitted: May 20, 2024
Date Accepted: Feb 21, 2025

The final, peer-reviewed published version of this preprint can be found here:

Optimizing the Pharmacotherapy of Vascular Surgery Patients at Hospital Admission and Discharge (PHAROS): Protocol for a Quasi-Experimental Clinical Uncontrolled Trial

Porubcova S, Lajtmanova K, Szmicsekova K, Slezakova V, Tomka J, Tesar T

Optimizing the Pharmacotherapy of Vascular Surgery Patients at Hospital Admission and Discharge (PHAROS): Protocol for a Quasi-Experimental Clinical Uncontrolled Trial

JMIR Res Protoc 2025;14:e60728

DOI: 10.2196/60728

PMID: 40106812

PMCID: 11966071

Optimising the pharmacotherapy of vascular surgery patients at hospital admission and at discharge (PHAROS): study protocol for quasi-experimental clinical uncontrolled trial

  • Slavka Porubcova; 
  • Kristina Lajtmanova; 
  • Kristina Szmicsekova; 
  • Veronika Slezakova; 
  • Jan Tomka; 
  • Tomas Tesar

ABSTRACT

Background:

Patient safety is the absence of preventable harm to a patient during the process of providing health care and reduction of the risk of unnecessary harm associated with health care to an acceptable minimum. It is coming in the forefront of interest worldwide in healthcare delivery.

Objective:

The aims of this protocol are to assess the impact of pharmaceutical care in collaboration with physicians on the prevalence of drug-related problems at hospital admission and discharge in vascular surgery patients.

Methods:

The study is conducted in the Vascular Surgery Department at the National Institute of Cardiovascular Diseases in Bratislava, Slovakia during 1-year period, included adult patients with carotid artery disease or lower extremity artery disease, taking ≥3 medications. The estimated population for this clinical uncontrolled trial is approximately 100. Medication reconciliation and medication reviews will be performed by hospital pharmacists at both admission and discharge. Pharmacist-proposed interventions will be documented and communicated to the physician, patients will be educated about their medications upon discharge.

Results:

The key focus area of this project will be the identification of drug-related problems, their occurrence and type. As a part of further research, analysis will be performed to describe the degree of acceptance of the proposed changes in pharmacotherapy by physicians, groups of drugs based on the Anatomical Therapeutic Chemical classification system with the highest incidence of drug-related problems and identify patients at highest risk for drug-related problems taking in consideration their personal and health information.

Conclusions:

This study should demonstrate that pharmacist-led interventions in collaboration with physicians could reducing the risks of pharmacotherapy and optimising medicines management and control systems for patient safety. Clinical Trial: ClinicalTrials.gov Identifier: NCT04930302


 Citation

Please cite as:

Porubcova S, Lajtmanova K, Szmicsekova K, Slezakova V, Tomka J, Tesar T

Optimizing the Pharmacotherapy of Vascular Surgery Patients at Hospital Admission and Discharge (PHAROS): Protocol for a Quasi-Experimental Clinical Uncontrolled Trial

JMIR Res Protoc 2025;14:e60728

DOI: 10.2196/60728

PMID: 40106812

PMCID: 11966071

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.